Nanexa

2,225

SEK

-3,05 %

Mindre end 1K følgere

NANEXA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

-3,05%

+6,46%

+93,48%

-2,41%

+3,01%

+158,12%

+1,14%

-78,27%

-72,8%

Nanexa is a drug delivery company with a proprietary platform that is used for the formulation of injectable depot drugs that create a supply of drugs to the blood. The PharmaShell process is based on ALD (Atomic Layer Deposition) technology, which encloses pharmaceutical particles with a thin shell and creates opportunities for pharmaceutical companies to develop new products. Nanexa has cooperation with several pharmaceutical companies, mainly around the Nordic market.

Markedsværdi

349,12 mio. SEK

Aktieomsætning

649,68 t SEK

Omsætning

24,36 mio.

EBIT %

-106,98 %

P/E

-

Udbytteafkast, %

-

Finanskalender

27.8

2025

Delårsrapport Q2'25

21.10

2025

Delårsrapport Q3'25

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Pressemeddelelse24.6.2025, 06.00

Presentation of NEX-22 phase I data: A once-monthly GLP-1 injection receives positive response at the 85th ADA Scientific Sessions in Chicago

Pressemeddelelse3.6.2025, 13.10

Nanexa Highlights NEX-22 and PharmaShell® During an Intensive Period of International Exposure

Pressemeddelelse23.5.2025, 07.15

All samples analyzed from the 30 mg dose group in the NEX-22 Phase I study

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Selskabsmeddelelse15.5.2025, 13.45

Bulletin from Nanexa’s Annual General Meeting

Pressemeddelelse8.5.2025, 11.06

Nanexa Receives Approval for Late Breaking Abstract at ADA Congress in Chicago in June

Eksterne analyser7.5.2025, 07.23

Nanexa: Clinical milestones align ahead of phase Ib/II and licensing push - Emergers

Nanexa continues to strengthen the foundation for the upcoming Phase Ib/II study in the NEX-22 project, with preliminary PK data from the final dose cohort confirming a dose-dependent profile. Management now targets treatment of the first patient in ...

Pressemeddelelse7.5.2025, 06.00

Emergers: Equity Research | NANEXA: Clinical milestones align ahead of phase Ib/II and licensing push

Selskabsmeddelelse6.5.2025, 06.15

Nanexa publishes interim report for January-March 2025

Selskabsmeddelelse5.5.2025, 19.35

Nanexa and Applied Materials terminates collaboration

Pressemeddelelse5.5.2025, 09.55

Analysis of the first samples from the 30 mg dose group in the NEX-22 Phase I study shows continued promising results

Selskabsmeddelelse22.4.2025, 10.50

Bridget Lacey Appointed Chief Business Officer at Nanexa

Selskabsmeddelelse11.4.2025, 07.15

Notice of annual general meeting in Nanexa AB (publ)

Selskabsmeddelelse10.4.2025, 07.40

Nanexa publishes annual report for 2024

Pressemeddelelse7.4.2025, 11.10

Continued Good Tolerability of NEX-22 at 30 mg Dose of Liraglutide in the NEX-22 Study

Pressemeddelelse25.3.2025, 07.49

Nanexa doses the last patients with 30 mg liraglutide in the NEX-22-01 study

Pressemeddelelse12.3.2025, 07.40

Nanexa doses first patient in the 30 mg dose group in the Phase I study with NEX-22

Eksterne analyser20.2.2025, 08.41

Nanexa: Targeting treatment of first patient in phase Ib/II with NEX-22 before year-end - Emergers

Nanexa’s Q4 report did not reveal much new, although the conference call provided welcome clarity on the rationale behind the extension of phase I with a higher dose (as dosing in the original phase I caused suspiciously few side effects). Management...

Pressemeddelelse20.2.2025, 07.00

Emergers: Equity Research | Nanexa AB: Targeting treatment of first patient in phase Ib/II with NEX-22 before year-end

Selskabsmeddelelse19.2.2025, 07.00

Nanexa publishes year-end report and Q4 report 2024

Selskabsmeddelelse14.2.2025, 12.50

Nomination Committee for the 2025 Annual General Meeting in Nanexa AB (publ)

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.